DVY vs XBI
iShares Select Dividend ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.38% for DVY.
- • DVY pays a higher dividend yield (3.29%).
Side-by-side metrics
| Metric | DVY | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.38% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.29% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $23.69B | $10.92B |
YTD return | 17.74% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.51 | 1.01 |
P/E ratio | 14.69 | — |
Last price | $162.67 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
DVY top holdings
| PFE | Pfizer Inc | 2.46% |
| MO | Altria Group Inc | 2.38% |
| HPQ | HP Inc | 2.16% |
| PRU | Prudential Financial Inc | 2.12% |
| TROW | T. Rowe Price Group Inc | 1.99% |
| OKE | ONEOK Inc | 1.84% |
| TGT | Target Corp | 1.68% |
| VZ | Verizon Communications Inc | 1.66% |
| CVX | Chevron Corp | 1.62% |
| KMB | Kimberly-Clark Corp | 1.61% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About DVY
DVY (iShares Select Dividend ETF) is 100 high-dividend-yielding US stocks. Managed by iShares, the fund carries $23.7B in assets under management, an expense ratio of 0.38%, a dividend yield of 3.29%. Its largest holding is Pfizer Inc (PFE), which represents 2.5% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 9.8%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.